Literature DB >> 6811189

The clotting defect in SLE.

M A Byron.   

Abstract

Haemorrhagic complications, though uncommon in SLE, may be life-threatening in individual patients, and they require treatment along appropriate lines. Thrombotic problems are more commonly encountered, and are a significant cause of morbidity and mortality. Not only is clinical thrombosis important in SLE, but there is increasing evidence that low-grade coagulopathy contributes substantially to many of the pathological features seen in lupus. The mechanisms involved in the pathogenesis of thrombosis have been discussed and their possible interrelationship is summarized in Figure 4, though it remains speculation that low-grade coagulopathy predisposes to clinical thrombosis. Several of these mechanisms may be operating during periods of disease activity; this was suggested in a recent study of clinical and histological features in SLE (Kant et al, 1981). The study was designed to look at the prevalence of glomerular thrombosis in SLE, and its significance as a histological feature. A striking association was observed between the presence of a circulating anticoagulant and the appearance of glomerular thrombosis on renal biopsy. Also, factor VIII levels were significantly increased and circulating platelets decreased in association with "active' histological features. On later re-biopsy glomerulosclerosis was a much more common finding if the first biopsy showed thrombosis, suggesting that thrombosis is a marker of more severe disease activity and inflammation. A greater understanding of the mechanisms promoting thrombosis will undoubtedly provide insight into the pathogenesis of SLE, as well as suggesting new therapeutic possibilities.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6811189

Source DB:  PubMed          Journal:  Clin Rheum Dis        ISSN: 0307-742X


  14 in total

1.  Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy.

Authors:  S Kobayashi; N Tamura; H Tsuda; C Mokuno; H Hashimoto; S Hirose
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

2.  Transient lupus anticoagulant and fansidar therapy.

Authors:  R F Jeffrey
Journal:  Postgrad Med J       Date:  1986-09       Impact factor: 2.401

3.  Circulating lupus type anticoagulant and pulmonary hypertension associated with mixed connective tissue disease.

Authors:  P Hainaut; E Lavenne; J M Magy; E G Lebacq
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

4.  Budd-Chiari syndrome as the major thrombotic complication of systemic lupus erythematosus with the lupus anticoagulant.

Authors:  M Averbuch; Y Levo
Journal:  Ann Rheum Dis       Date:  1986-05       Impact factor: 19.103

5.  Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus.

Authors:  M A Byron; M J Allington; H M Chapel; A G Mowat; S A Cederholm-Williams
Journal:  Ann Rheum Dis       Date:  1987-10       Impact factor: 19.103

6.  Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.

Authors:  G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

7.  Axillary vein thrombosis in adolescent onset systemic sclerosis.

Authors:  A Leak; K J Patel; E G Tuddenham; J D Pearson; P Woo
Journal:  Ann Rheum Dis       Date:  1990-07       Impact factor: 19.103

Review 8.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

9.  Current understanding of systemic lupus erythematosus.

Authors:  G R Hughes
Journal:  Inflammation       Date:  1984-06       Impact factor: 4.092

10.  Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant.

Authors:  M L Boey; C B Colaco; A E Gharavi; K B Elkon; S Loizou; G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.